NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOL

HEIDELBERG, Germany, and CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical...

Related Keywords

Germany ,Heidelberg ,Baden Wüberg ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Washington ,American ,Christian Roesky ,Novaliq Gmb ,Prnewswire Novaliq ,Johnd Sheppard ,Gmbh Co ,Health Sciences ,Novaliq Inc ,American Cataract ,Refractive Surgery ,Eastern Virginia Medical School ,Mid Atlantic Medical Director ,Eye Care Partners ,Chief Executive Officer ,Corneal Fluorescein Staining ,Hopp Biotech ,